Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares are trading lower after the company announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significance in the primary efficacy endpoint.
Fostamatinib is currently being evaluated in a Phase 3 randomized, double-blind, placebo-controlled clinical study in 90 patients with wAIHA who have failed at least one prior treatment.
